SGIOF News and Press, Shionogi & Co Ltd From 07/20/22

A group of health experts in Japanese health ministry delayed emergency approval on Wednesday for the COVID-19 pill developed by Osaka-based drugmaker Shionogi & Co. ( OTCPK:SGIOF ) ( OTCPK:SGIOY ), citing the need to continue discussions on the drug. The delay marks the...

Health experts advising the Japanese drug regulators postponed a decision on whether to endorse a COVID-19 pill developed by Shionogi & Co. (OTCPK:SGIOF) (OTCPK:SGIOY) and its South Korean partner, Il Dong Pharmaceutical Co. The panel of experts concluded that additional “careful d...

Paxlovid, the COVID-19 pill developed by Pfizer (NYSE:PFE), is set to generate $23.6 billion in revenue in 2022 to become one of the fastest-selling treatments of all time, London-based data analytics firm Airfinity Ltd. said Friday, according to Bloomberg. While the consensus ...

Ascletis Pharma (OTCPK:ASCLF) said data from antiviral cellular assays suggested that its drug ASC11 showed potential to be effective treatment for COVID-19. The Chinese company said that in antiviral cellular assays, antiviral potency of ASC11 was 31-fold of that of Nirmatrelvir, a comp...

Shionogi (OTCPK:SGIOF) (OTCPK:SGIOY) signed a basic agreement with the Ministry of Health, Labor and Welfare (MHLW) to supply its oral COVID-19 drug S-217622 in Japan. The company said it expects the Japanese government to buy 1M courses of S-217622, following approval of the drug, and w...

ViiV Healthcare, owned by GlaxoSmithKline (NYSE:GSK) with Pfizer (NYSE:PFE) and Shionogi (OTCPK:SGIOF) (OTCPK:SGIOY), announced on Thursday that the US Food and Drug Administration (FDA) greenlighted a label update for its HIV medication, Cabenuva. The latest update has made the oral lead-in ...

Shionogi (OTCPK:SGIOF) (OTCPK:SGIOY) said the U.S. FDA cleared its investigational new drug (IND) for oral COVID-19 drug S-217622, allowing a global phase 3 trial to proceed as part of the ACTIV-2 program. The phase 3 trial, ACTIV-2d (also known as SCORPIO-HR), will evalua...

Shionogi's (OTCPK:SGIOY +1.9%) COVID-19 vaccine achieved its primary endpoint of increasing neutralizing antibody titers after 28 days when used as a booster shot in a phase 2/3 trial. The non-inferiority of Shionogi's (OTCPK:SGIOF) shot was compared against Pfizer (PFE +1.3%)/BioNTech's (BNT...

Shionogi (OTCPK:SGIOF) (OTCPK:SGIOY) filed for manufacturing and sales approval of its oral COVID-19 drug S-217622, in Japan. The company said it completed the analysis of primary endpoints in the phase 2b part of a phase 2/3 trial of S-217622, following which it requested revi...

The following slide deck was published by Shionogi & Co., Ltd. in conjunction with their 2022 Q3 earnings call. For further details see: Shionogi & Co., Ltd. 2022 Q3 - Results - Earnings Call Presentation